Nextage Therapeutics Ltd
TASE:NXTG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nextage Therapeutics Ltd
TASE:NXTG
|
IL |
Balance Sheet
Balance Sheet Decomposition
Nextage Therapeutics Ltd
Nextage Therapeutics Ltd
Balance Sheet
Nextage Therapeutics Ltd
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
2
|
1
|
3
|
0
|
1
|
2
|
3
|
1
|
0
|
0
|
|
| Cash Equivalents |
2
|
1
|
3
|
0
|
1
|
2
|
3
|
1
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
2
|
1
|
3
|
1
|
1
|
3
|
4
|
1
|
1
|
0
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
10
|
10
|
9
|
5
|
4
|
1
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
13
N/A
|
11
-13%
|
12
+8%
|
5
-56%
|
6
+10%
|
4
-32%
|
4
+5%
|
2
-65%
|
1
-28%
|
0
-68%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
2
|
1
|
2
|
1
|
1
|
1
|
1
|
2
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
|
| Total Current Liabilities |
2
|
2
|
1
|
2
|
1
|
2
|
3
|
2
|
4
|
6
|
|
| Long-Term Debt |
1
|
2
|
2
|
1
|
0
|
1
|
1
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Other Liabilities |
4
|
6
|
5
|
4
|
2
|
1
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
8
N/A
|
9
+11%
|
8
-13%
|
7
-11%
|
2
-68%
|
3
+14%
|
5
+73%
|
2
-48%
|
4
+68%
|
6
+47%
|
|
| Equity | |||||||||||
| Common Stock |
1
|
0
|
0
|
0
|
0
|
0
|
30
|
35
|
61
|
0
|
|
| Retained Earnings |
88
|
106
|
111
|
120
|
122
|
22
|
30
|
35
|
65
|
69
|
|
| Additional Paid In Capital |
93
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
63
|
|
| Other Equity |
0
|
108
|
116
|
119
|
126
|
24
|
30
|
35
|
0
|
0
|
|
| Total Equity |
5
N/A
|
2
-53%
|
4
+90%
|
2
N/A
|
4
N/A
|
1
-61%
|
0
N/A
|
1
-240%
|
3
-237%
|
6
-90%
|
|
| Total Liabilities & Equity |
13
N/A
|
11
-13%
|
12
+8%
|
5
-56%
|
6
+10%
|
4
-32%
|
4
+5%
|
2
-65%
|
1
-28%
|
0
-68%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
1
|
1
|
1
|
2
|
25
|
26
|
28
|
30
|
34
|
|